SPRO Stock Overview
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Spero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$2.00 |
| 52 Week Low | US$0.99 |
| Beta | 0.58 |
| 1 Month Change | -13.29% |
| 3 Month Change | 6.38% |
| 1 Year Change | -14.29% |
| 3 Year Change | -88.72% |
| 5 Year Change | -87.85% |
| Change since IPO | -86.96% |
Recent News & Updates
Recent updates
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Sizing Up Spero Therapeutics
Oct 15Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 11Are Institutions Heavily Invested In Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Shares?
Feb 23Shareholder Returns
| SPRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.8% | -5.0% | -3.5% |
| 1Y | -14.3% | -1.7% | 20.2% |
Return vs Industry: SPRO underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: SPRO underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| SPRO volatility | |
|---|---|
| SPRO Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPRO has not had significant price volatility in the past 3 months.
Volatility Over Time: SPRO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 46 | Sath Shukla | sperotherapeutics.com |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics, Inc. Fundamentals Summary
| SPRO fundamental statistics | |
|---|---|
| Market cap | US$79.22m |
| Earnings (TTM) | US$22.81m |
| Revenue (TTM) | US$103.78m |
3.5x
P/E Ratio0.8x
P/S RatioIs SPRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRO income statement (TTM) | |
|---|---|
| Revenue | US$103.78m |
| Cost of Revenue | US$51.44m |
| Gross Profit | US$52.34m |
| Other Expenses | US$29.54m |
| Earnings | US$22.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 50.43% |
| Net Profit Margin | 21.98% |
| Debt/Equity Ratio | 0% |
How did SPRO perform over the long term?
See historical performance and comparison